<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520997</url>
  </required_header>
  <id_info>
    <org_study_id>05DF1910</org_study_id>
    <nct_id>NCT04520997</nct_id>
  </id_info>
  <brief_title>Restylane Defyne in a Stepwise Treatment Approach</brief_title>
  <official_title>A Randomized, Evaluator-Blinded Study to Evaluate Facial Harmony and Subject Satisfaction Using Restylane Defyne in a Stepwise Treatment Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week study to evaluate the effectiveness and safety of Restylane Defyne when&#xD;
      using two different injection approaches, stepwise down-up vs. top-down, when treating the&#xD;
      lower face.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Actual">September 10, 2021</completion_date>
  <primary_completion_date type="Actual">September 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants assessed as at least improved on the GAIS</measure>
    <time_frame>Week 3, 6 and 9</time_frame>
    <description>Aesthetic improvement after treatment in chin and nasolabial fold/marionette line, respectively, and in combination is evaluated by Treating Investigator. Aesthetic improvement is evaluated with the 5-graded Global Aesthetic Improvement Scale (GAIS) with options 'worse', 'no change', 'improved', 'much improved', 'very much improved'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants assessed as having a natural treatment result</measure>
    <time_frame>Week 3, 6 and 9</time_frame>
    <description>To evaluate naturalness of the treatment result, assessed by Treating Investigator using directed questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants agreeing with statements in a satisfaction questionnare</measure>
    <time_frame>Week 3, 6 and 9</time_frame>
    <description>Subject satisfaction treating chin versus treating nasolabial fold/marionette line, respectively, and in combination, is evaluated. Evaluation made via subject satisfaction questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Lower Face Folds and Lines</condition>
  <arm_group>
    <arm_group_label>Down-up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive injections in the chin area at baseline and in the nasolabial folds (NLFs) and marionette lines (MLs) at week 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Top-down</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive injections in the nasolabial folds (NLFs) and marionette lines (MLs) at baseline and in the chin area at week 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Defyne</intervention_name>
    <description>Hyaluronic acid filler</description>
    <arm_group_label>Down-up</arm_group_label>
    <arm_group_label>Top-down</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects willing to comply with the requirements of the study and providing a signed&#xD;
             written informed consent&#xD;
&#xD;
          -  Subjects willing to undergo augmentation and correction therapy in the studied&#xD;
             indications&#xD;
&#xD;
          -  Adult males or non-pregnant, non-breastfeeding females and women of non-child bearing&#xD;
             potential over the age of 21&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel&#xD;
             or to gram-positive bacterial proteins&#xD;
&#xD;
          -  Previous use of any permanent (non-biodegradable) treatment, lifting threads,&#xD;
             permanent implants or autologous fat below the level of the horizontal line from the&#xD;
             lower orbital rim&#xD;
&#xD;
          -  Previous use of any semi-permanent treatment (e.g., calcium hydroxylapatite or&#xD;
             Poly-L-Lactic acid) below the level of the horizontal line from the lower orbital rim&#xD;
             within 24 months of the baseline visit&#xD;
&#xD;
          -  Previous use of any HA based or collagen based biodegradable facial tissue&#xD;
             augmentation therapy below the level of the horizontal line from the lower orbital rim&#xD;
             within 12 months of the baseline visit&#xD;
&#xD;
          -  Previous facial surgery, within 12 months, below the level of the horizontal line from&#xD;
             the lower orbital rim&#xD;
&#xD;
          -  Participation in any interventional clinical study within 30 days of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Q-Med AB</last_name>
    <role>Study Director</role>
    <affiliation>Q-Med AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>SÃ£o Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

